ADAPTED THERAPY REGIMEN GROUP

MEMBERS:

71

COMMITTEE CHAIRS

Introduction

  • The SIOP PODC Adapted Therapy Regimen Group promotes the development of universal templates and pragmatic guidelines for the treatment of Childhood Cancer in the according to the specific setting of pediatric care. The settings 0, 1, 2, 3 and 4, are adjudicated a framework describing the elements that these guidelines should contain.
  • Bring the current batch of guidelines to publication and identify the next set of malignancies that would benefit from an adapted intensity protocol, and initiate discussions with potential writing group convenors.

An Adapted Treatment Regimen WG Symposium took place at SIOP Toronto 2014 with the aim of bringing together the experiences and outcomes of low and low-middle income countries, and a first view of the Framework of Adapted Therapies  (Scott Howard). We are seeking new members, particularly from countries with limited resources. We have members who can communicate in a range of languages, including Spanish, Hindi, Dutch and French, but we strive for additional language diversity providing a focus for cross‐disciplinary interaction and collaboration. Our main goal is to partner and advocate with healthcare teams world-wide to improve care of children with cancer.

Current Activities

Creation of a SIOP PODC Adapted Therapy Framework by Setting for use in low- and middle-income countries. Manuscript finalized.

ATR usage among LMIC: a survey from SIOP Cape Town 2015. Data analysis in progress.

Active writing groups:

AML – chaired by Gertjan Kaspers

Hepatoblastoma – chaired by Mike Sullivan and SIOPEL

Hodgkin Lymphoma – chaired by Monika Metzger

Low Grade Glioma – chaired by Simon Bailey

Osteosarcoma – chaired by Carlos Rodriguez-Galindo and Paulo Friedrich

Recent Publications

Parkes J, Hendricks M, Ssenyonga P, Mugamba J, Molyneux E, Schouten-van Meeteren A, Qaddoumi I, Fieggen G, Luna-Fineman S, Howard S, Mitra D, Bouffet E, Davidson A, Bailey S. SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatr Blood Cancer. 2015; 62: 553-64.

Parikh NS, Howard SC, Chantada GC, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay K. Recommendations for neuroblastoma in low- and middle-income settings. Pediatric Blood & Cancer 2015, 62: 1305-16.